Kenneth C Kalunian
Overview
Explore the profile of Kenneth C Kalunian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
3056
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morand E, van Vollenhoven R, Furie R, Kalunian K, Manzi S, Abreu G, et al.
Ann Rheum Dis
. 2025 Feb;
PMID: 39948001
Objectives: To investigate the long-term impact of anifrolumab versus placebo on lupus low disease activity state (LLDAS) and definition of remission in systemic lupus erythematosus (DORIS) attainment in patients with...
2.
Barber M, Ugarte-Gil M, Hanly J, Urowitz M, St-Pierre Y, Gordon C, et al.
Ann Rheum Dis
. 2024 May;
83(10):1295-1303.
PMID: 38754981
Objectives: This study aims to determine the independent impact of definitions of remission/low disease activity (LDA) on direct/indirect costs (DCs, ICs) in a multicentre inception cohort. Methods: Patients from 31...
3.
Krustev E, Hanly J, Chin R, Buhler K, Urowitz M, Gordon C, et al.
Lupus Sci Med
. 2024 Apr;
11(1).
PMID: 38599670
Background: Cranial neuropathies (CN) are a rare neuropsychiatric SLE (NPSLE) manifestation. Previous studies reported that antibodies to the kinesin family member 20B (KIF20B) (anti-KIF20B) protein were associated with idiopathic ataxia...
4.
Horisberger A, Griffith A, Keegan J, Arazi A, Pulford J, Murzin E, et al.
bioRxiv
. 2024 Jan;
PMID: 38293222
Lupus nephritis (LN) is a frequent manifestation of systemic lupus erythematosus, and fewer than half of patients achieve complete renal response with standard immunosuppressants. Identifying non-invasive, blood-based pathologic immune alterations...
5.
Strand V, OQuinn S, Furie R, Morand E, Kalunian K, Schwetje E, et al.
Lancet Rheumatol
. 2024 Jan;
4(3):e198-e207.
PMID: 38288936
Background: The British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) is a validated global measure of treatment response in systemic lupus erythematosus (SLE) clinical trials but does not include...
6.
Furie R, Morand E, Bruce I, Manzi S, Kalunian K, Vital E, et al.
Lancet Rheumatol
. 2024 Jan;
1(4):e208-e219.
PMID: 38229377
Background: Type I interferons are involved in systemic lupus erythematosus (SLE) pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I interferon receptor subunit 1, suppressed...
7.
What Bedside Skills Could the Modern Rheumatologist Possess? Part II. "Certain Technical Procedures"
Ike R, McCoy S, Kalunian K
J Clin Rheumatol
. 2023 Nov;
PMID: 37983677
Rheumatologists have never been reluctant to adopt procedures that might enhance their diagnostic or therapeutic powers. Their propensity to penetrate the joints of the patients they were treating set them...
8.
Ike R, McCoy S, Kalunian K
J Clin Rheumatol
. 2023 Aug;
PMID: 37553898
The hands-on aspect of rheumatologic practice serves to balance its more cerebral features with the everyday necessity to touch patients to assess their condition, obtain samples for diagnosis, and deliver...
9.
Nguyen Y, Blanchet B, Urowitz M, Hanly J, Gordon C, Bae S, et al.
Arthritis Rheumatol
. 2023 Jul;
75(12):2195-2206.
PMID: 37459273
Objective: The goals of this study were to assess the associations of severe nonadherence to hydroxychloroquine (HCQ), objectively assessed by HCQ serum levels, and risks of systemic lupus erythematosus (SLE)...
10.
Petri M, Bruce I, Dorner T, Tanaka Y, Morand E, Kalunian K, et al.
Lancet
. 2023 Feb;
401(10381):1011-1019.
PMID: 36848919
Background: Baricitinib is an oral selective inhibitor of Janus kinase 1 and 2 approved for the treatment of rheumatoid arthritis, atopic dermatitis, and alopecia areata. In a 24-week phase 2...